DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Planet Labs ( $PL )moving toward strategic infrastructure
The new delay on Middle East imagery is not enough, by itself, to make a full article. But as an editorial trigger, it is strong. It forces a bigger question: is Planet still mainly a commercial satellite-imagery company, or is it becoming a strategic information utility that increasingly operates inside the security architecture of the United States and its allies?
Rocket Pharmaceuticals Inc ( $RCKT ) refreshes its ATM 17 days before the March 28 PDUFA
This was not a classic overnight equity raise. Rocket filed a new ATM framework with Cantor Fitzgerald, terminated the prior TD/Cowen agreement, and did so with the March 28, 2026 PDUFA for KRESLADI now close enough to matter in every financing read-through.
X and the Nasdaq question
A careful bilingual deep dive on whether X could realistically find a route to Nasdaq exposure after today’s Reuters reports, why the answer is more indirect than many headlines suggest, and how payments, regulation, competition and corporate structure change the picture.
Capricor Therapeutics Inc ( $CAPR ) FDA PDUFA Approval Target (August 22, 2026)
On March 10, 2026, Capricor Therapeutics announced that the FDA has lifted its Complete Response Letter (CRL) and resumed review of the Biologics License Application (BLA) for Deramiocel. The agency assigned a new PDUFA target action date of August 22, 2026—a pivotal moment after months of regulatory uncertainty.
Castellum ($CTM) — 2025 repaired the story
Castellum came out of 2025 looking cleaner, less leveraged and more credible than it did a year earlier. Revenue grew, operating losses narrowed sharply, cash improved, debt was almost fully gone by year-end and then fully eliminated shortly after. The central question now is no longer whether CTM can tell a better story, but whether it can turn backlog, contract wins and pipeline into durable margins and more repeatable cash generation in 2026.
ImmunityBio (NASDAQ: IBRX) — FDA resubmission
What happened today
Today’s real headline is straightforward: ImmunityBio announced that it has resubmitted the supplemental biologics license application to the FDA for ANKTIVA plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
According to the company, it had already submitted information requested by the FDA in February 2026, but in March the agency then requested updated efficacy information based on longer follow-up, which ImmunityBio says has now been included in the resubmitted package.
Ondas (NASDAQ: $ONDS) — preliminary 2025 earnings beat and Mistral merger agreement Updated mach 10
A long-form bilingual deep dive on what changed in Ondas’ preliminary fourth-quarter and full-year 2025 update, why the revenue beat matters more than the raw numbers alone, how the Mistral agreement changes the strategic map, and what investors should watch next as ONDS tries to move from fast-growing defense-tech vendor to a broader autonomous systems platform with prime-contractor access.
IMMP under halt: what may really be behind it ( $IMMP )
Immutep’s Nasdaq-listed ADRs were halted on Friday, March 6, 2026 under code T1 / News Pending. On the Australian side, the public halt notice points to an announcement regarding the outcome of the pre-specified interim futility analysis for the Phase III TACTI-004 trial. That single detail matters a lot: it shifts the center of gravity from wild speculation to a very specific clinical event. What follows is a structured look at the facts, the company, the pipeline, and the full range of plausible scenarios.
Weekly Recap & Briefing – Oil Shock, Weak Jobs, Iran War and a More Selective Tape (Mar 2–6, 2026)
The week that closed on Friday 6 March was the first full trading week in which markets had to process the new Middle East war regime rather than just react to a weekend headline. The U.S.–Israeli campaign against Iran and the retaliation that followed kept energy, shipping and inflation risk at the centre of the tape, while the S&P 500 ended the week lower, the VIX climbed to its highest level since April 2025 and Brent crude pushed above 90 dollars a barrel. On top of that, Friday’s U.S. jobs report added a second layer of stress: payrolls unexpectedly fell and the unemployment rate moved up, pushing investors into an awkward mix of growth fear and inflation fear at the same time.
PMV Pharmaceuticals Inc ( $PMVP )
PMV Pharmaceuticals is a precision oncology company built around rezatapopt (PC14586), an oral small-molecule reactivator of p53 designed for tumors harboring the TP53 Y220C mutation. The story matters because TP53 is one of the most important tumor suppressor genes in cancer biology, and because PMV has now moved from mechanism-only interest into clinically visible efficacy data. The company’s registrational PYNNACLE study has produced an overall 34% ORR across evaluable Phase 2 patients and a 46% ORR in the ovarian cohort at the September 4, 2025 cutoff, with the company later reporting a 50% ORR in the same ovarian cohort after that cutoff. FDA Orphan Drug Designation granted on March 2, 2026 adds meaningful regulatory support. PMV says it plans to submit an NDA in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.
Obesity Medicines 2026 — Part 1: sector map for investors
A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares.
Obesity Medicines 2026 Part 2
Part 2 moves from the sector to the stocks themselves. Each company is examined through the same lens: ticker, core asset, stage, regulatory standing, commercial position, why the market cares, bull case, bear case and the next likely stock-moving issues. The goal is not to crown a winner but to show what each public name really is today.
ONDS vs DRSHF (ASX:DRO) — two ways to play the drone / counter-drone boom
ONDS vs DRSHF (ASX:DRO) — Counter-Drone Deep Dive Comparison | Merlintrader EN IT Comparative Deep Dive ONDS vs DRSHF (ASX:DRO) — two ways to play the drone / counter-drone boom This report compares Ondas and DroneShield from every angle that…
ZenaTech Inc ( $ZENA ) deep dive on the story filings ownership governance
A structured review built around the most relevant SEC filings from the last year, with special attention to what is real already, what is still mostly forward story, how the acquisition machine is being used to create revenue, and where the governance and financing risks are concentrated.
Drone stocks explained: the listed names that matter $AVA $ONDS $RCAT $DPRO $KTOS $UMAC
A comparative, long-form guide to the main quoted drone and counter-drone names retail investors keep putting in the same basket — from AeroVironment and Kratos to Ondas, Red Cat, Draganfly and Unusual Machines — with a focus on what each company really does, where the real business sits, and where the story is still more narrative than scale.
Rumble Inc ( $RUM )
Executive summary
Rumble is no longer just a politically differentiated video platform. After FY 2025 results, the company is trying to present itself as a three-layer story: a creator and media platform, an advertising and subscription monetization engine, and a cloud / GPU infrastructure business that could become much more material if the Northern Data transaction closes.
The War Economy
The market is no longer treating Middle East escalation as a passing geopolitical shock. It is increasingly pricing it as a broader economic regime: one that reprices oil and LNG, lifts defense and dual-use space names, pressures airlines and small caps, and forces investors to rethink the physical vulnerability of cloud infrastructure
Three March PDUFAs retail biotech traders are watching most closely
March is packed with biotech catalysts, but for many retail traders the shortlist comes down to three names: Lantheus, Aldeyra and Rocket Pharmaceuticals. They are very different stories — one radiopharma platform name, one dry-eye binary, one rare-disease gene-therapy approval setup — but all three have the ability to move fast around FDA timing, market expectations and headline interpretation.
Horizon Aircraft Ltd ( $Hovr ) lower-cost VTOL pitch gets sharper
Horizon Aircraft’s latest update was not about a signed order or a certification milestone. It was a commercial positioning update: management is now leaning harder on the argument that the Cavorite X7 could operate at materially lower cost than helicopters, while continuing a visible March–April industry-events circuit to keep the platform in front of operators, investors and policy stakeholders.
Planet Labs ( $PL ) Europe, defence and sovereign satellite demand
Planet is no longer a simple “satellite imagery story” to be judged on a vague promise of future demand. The company now sits at the intersection of recurring Earth-data subscriptions, defence and intelligence workflows, sovereign demand for dedicated capability, and a broader European push toward strategic autonomy in space and geospatial data. The stock has already been re-rated hard, so the real question is no longer whether Planet has become more relevant. It clearly has. The real question is whether this growing strategic relevance can convert into cleaner revenue quality, stronger margins, and a more durable case into the next earnings event.